Page 6 - Beckley Psytech News Today

GODALMING, UK / ACCESSWIRE / December 22, 2022 / Condor Gold Plc (AIM:CNR)(TSX:COG) announces that further to its announcement of 28 November 2022 the Company has today appointed Denham Eke as a Non-Executive

Insider's annual 100 People Transforming Business 2022 list is live. Here's the list of honorees in the healthcare sector.

Beckley Psytech has dosed the first participant in their Phase I single-ascending dose (SAD) study of ELE-101, with top-line results expected in H1 2023.ELE-101 is a patent-protected, next-generation formulation of psilocin, the active metabolite of psilocybin, under clinical development for depression.ELE-101 is th...

Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to dose and fast-acting. The company was formed and incubated by RA Capital Management, which led the startup’s Series A round of financing.

Beckley Psytech Limited, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announced that it has entered into a definitive agreement to acquire clinical-stage life science company, Eleusis Therapeutics Limited ("Eleusis") ...

Europe’s psychedelic sector is becoming increasingly mainstream, here are the top startups in the space, according to investors

/PRNewswire/ -- Two doses of psilocybin, a compound found in psychedelic mushrooms, reduces heavy drinking by 83% on average among heavy drinkers when combined...

This randomized clinical trial evaluates the combination of psychotherapy with psilocybin vs active placebo in patients with alcohol use disorder.

Funding for companies developing drugs for neurological disorders is seeing an uptick. Here are the firms that have raised the most cash to date.

From January to June 2022, around €2bn was raised by new VC funds in Europe. But who are the new kids on the block?